- Home
- REVB vs CWD Comparison
REVB vs CWD Comparison
Compare REVB & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- CWD
- Stock Information
- Founded
- REVB 2020
- CWD 2009
- Country
- REVB United States
- CWD United States
- Employees
- REVB N/A
- CWD N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- REVB Health Care
- CWD Finance
- Exchange
- REVB Nasdaq
- CWD Nasdaq
- Market Cap
- REVB 3.8M
- CWD 4.5M
- IPO Year
- REVB N/A
- CWD 2023
- Fundamental
- Price
- REVB $2.88
- CWD $2.54
- Analyst Decision
- REVB
- CWD
- Analyst Count
- REVB 0
- CWD 0
- Target Price
- REVB N/A
- CWD N/A
- AVG Volume (30 Days)
- REVB 269.2K
- CWD 42.0K
- Earning Date
- REVB 08-08-2025
- CWD 08-11-2025
- Dividend Yield
- REVB N/A
- CWD N/A
- EPS Growth
- REVB N/A
- CWD N/A
- EPS
- REVB N/A
- CWD N/A
- Revenue
- REVB N/A
- CWD $35,429,000.00
- Revenue This Year
- REVB N/A
- CWD N/A
- Revenue Next Year
- REVB N/A
- CWD $31.12
- P/E Ratio
- REVB N/A
- CWD N/A
- Revenue Growth
- REVB N/A
- CWD N/A
- 52 Week Low
- REVB $2.11
- CWD $2.33
- 52 Week High
- REVB $168.00
- CWD $16.00
- Technical
- Relative Strength Index (RSI)
- REVB 44.79
- CWD 34.80
- Support Level
- REVB $2.97
- CWD $2.60
- Resistance Level
- REVB $3.18
- CWD $3.63
- Average True Range (ATR)
- REVB 0.23
- CWD 0.29
- MACD
- REVB 0.13
- CWD -0.05
- Stochastic Oscillator
- REVB 60.37
- CWD 16.15
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.